in vitro News and Research

RSS

EraGen, Applied BioCode partner to commercialize molecular diagnostics

Applied BioCode, Inc. and EraGen Biosciences Inc. today announced that they have entered into a strategic partnership and license agreement. The agreement provides EraGen with access to Applied BioCode's Barcoded Magnetic Bead technology and the CE-marked BioCode-1000 system.

19 Apr 2011

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of highly-resistant bacteria, commonly referred to as 'superbugs.'

16 Apr 2011

Mandatory single embryo transfers for IVF may decrease risk and cost

The number of couples struggling with infertility is on the rise, and these couples often use assisted reproductive technologies, like in vitro fertilization (IVF), to get pregnant. Although IVF can be successful, it can also increase the risk of multiple pregnancies, which are often caused by transferring more than one embryo. Twins and triplets are likely to be born prematurely, and, as a result, many have medical complications.

15 Apr 2011

Researchers develop Short-CGH method for preimplantation genetic screening

A Short Comparative Genomic Hybridisation method has been developed to carry out preimplantation genetic screening by analysing all chromosomes and transferring selected embryos to the recipient uterus in the same in vitro fertilisation cycle. This eliminates the need to freeze them.

15 Apr 2011

Researchers classify chronic ulcerative stomatitis as a new autoimmune disease

In the first study investigating the origins of a little-known condition called chronic ulcerative stomatitis, researchers at Tufts University School of Dental Medicine provide evidence that an autoimmune response contributes to the painful oral sores that characterize the disease. The study findings support the classification of CUS as a new autoimmune disease.

15 Apr 2011

Study shows neutralizing antibodies to C5a protein may prevent heart failure

New research published online in The FASEB Journal details research in rats and mice that offers hope for stopping the devastating, and often fatal, effects of sepsis in humans. In the study, University of Michigan researchers show how neutralizing the effects of a key protein fragment, called C5a, used by the immune system to attract white blood cells may ultimately prevent heart failure.

12 Apr 2011

Cellix expands European distribution network with Tebu-bio

Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.

11 Apr 2011

New dengue test receives FDA marketing clearance

The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.

11 Apr 2011

Cepheid receives FDA clearance for new assay to detect C. difficile infection

The U.S. Food and Drug Administration today cleared a test called the Cepheid Xpert C. difficile/Epi assay that is designed to rapidly detect the toxin B gene associated with Clostridium difficile infection, a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death in severe cases.

11 Apr 2011

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris Group announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.

8 Apr 2011

Caffeine disrupts glucose metabolism and may contribute to type 2 diabetes

A growing body of research suggests that caffeine disrupts glucose metabolism and may contribute to the development and poor control of type 2 diabetes, a major public health problem.

8 Apr 2011

Scientists identify two molecules that enable cancer spread

For many types of cancer, the original tumor itself is usually not deadly. Instead, it's the spread of a tiny subpopulation of cells from the primary tumor to other parts of the body—the process known as metastasis—that all too often kills the patient.

8 Apr 2011

Luminex receives Medical Design Excellence Award for innovative MAGPIX system

Luminex Corporation has won a 2011 Medical Design Excellence Award in the category of In Vitro Diagnostics for its innovative MAGPIX system. Introduced in 2010, MAGPIX is a compact, versatile laboratory analysis platform designed to improve productivity by delivering multiple highly accurate, reproducible results from a single sample.

From Luminex 8 Apr 2011

FDA to discuss 2008 immunogenicity directives with European industry experts at Pharma IQ

This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic Proteins CBER from FDA will meet with European industry experts at Pharma IQ's to discuss FDA directives on immunogenicity introduced in 2008.

6 Apr 2011

Specific lipids in tumours linked to cancer progression and patient survival

Activation of lipid metabolism is an early event in carcinogenesis and a central hallmark of many cancers. However, the precise molecular composition of lipids in tumours remains generally poorly characterised. Scientists from VTT Technical Research Centre of Finland and the Charité Hospital have found lipids in tumours which are associated with cancer progression.

6 Apr 2011

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

Study finds low multiple birth rates in 15 states that provide insurance coverage for IVF

Faced with the prospect of costly in vitro fertilization but with no help from insurance coverage, some infertile couples feel pressure to transfer multiple embryos in an attempt to ensure that the IVF is a success.

6 Apr 2011

Adipocytes associated with breast cancer could amplify 'aggressive' effect of tumors in obese patients

Apart from its direct effect on health (such as cardiovascular diseases and diabetes), obesity is increasingly suspected of playing a role in the prognosis of breast cancer and, in particular, its propensity to spread. However, no direct cause and effect relationship had been demonstrated until now. This breakthrough has finally been made through the collaborative work of two teams of researchers from Inserm, CNRS and the Université Paul Sabatier.

6 Apr 2011

Caliper's CDAS unit enters cancer research collaboration with Denver-based CHI

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life-sciences research, today announced that its Caliper Discovery Alliances and Services unit has formed a research collaboration with Denver-based Catholic Health Initiatives, one of the nation's largest health systems.

6 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011